Healthcare experts have found the epigenetics market to be one of the highest booming markets, and the global market is predicted to grow at a CAGR of 17.11% during the forecast period 2021-2031.

1. 1
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
res
Attribution: https://pixabay.com/photos/tire-rim-car-mechanic-114259/
Focus on Product, Mechanism,
Technology, Application, End User, and
Region
Analysis and Forecast: 2021-2031
November 2021
Epigenetics
Market -
A Global and
Regional Analysis
Table of Content

2. 2
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2021 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3. 3
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
Table of Content
Executive Summary..........................................................................19
Research Methodology.....................................................................25
1. Markets .....................................................................................30
1.1 Product Definition............................................................................................31
1.1.1 Inclusion and Exclusion .............................................................................31
1.2 Market Scope ...................................................................................................31
1.2.1 Scope of the Study......................................................................................31
1.2.2 Key Questions Answered in the Report ....................................................32
1.3 Market Overview ..............................................................................................33
1.3.1 Market Definition .........................................................................................33
1.3.2 Emerging Applications of Epigenetics......................................................33
1.3.2.1 DNA Methylation................................................................................................ 33
1.3.2.2 Histone Modification .......................................................................................... 34
1.3.2.3 RNA Modification............................................................................................... 35
1.3.3 Market Footprint and Growth Potential, $Million, 2020-2031...................35
1.3.4 Disruption in Global Epigenetics Market Due to COVID-19 .....................36
1.3.5 COVID-19 Affecting Supply Chain of Global Epigenetics Market............37
1.3.6 Interruption in Research and Clinical Development and Commercial
Operation ...............................................................................................37
1.3.6.1 Research and Clinical Development.................................................................. 37
1.3.6.2 Commercial Operation....................................................................................... 38
1.3.7 Navigating Crisis Recovery and Looking to the Future...........................38
2. Industry Insights ........................................................................39
2.1 Overview...........................................................................................................40
2.2 Legal Requirements and Frameworks in Europe..........................................41
2.3 Legal Requirements and Frameworks in Asia-Pacific..................................41
2.3.1 China ............................................................................................................41
2.3.2 Japan............................................................................................................42
2.4 Reimbursement Analysis................................................................................42

4. 4
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
2.5 Iceberg Analysis – Global Epigenetics Market..............................................43
3. Market Dynamics .......................................................................45
3.1 Overview...........................................................................................................46
3.2 Impact Analysis ...............................................................................................46
3.3 Market Drivers..................................................................................................47
3.3.1 Epigenetics Inclined by Rising Prevalence of Cancer .............................47
3.3.2 Strategic Initiatives by Key Market Players...............................................48
3.3.3 Increasing Government Initiatives in the Field of Epigenetics................49
3.4 Market Restraints.............................................................................................50
3.4.1 High Cost of Instruments............................................................................50
3.4.2 Dearth of Skilled Professionals in Epigenetic Research .........................51
3.5 Market Opportunities.......................................................................................52
3.5.1 Technological Advancement Toward Innovation in Epigenetics............52
3.5.1.1 Epigenetics & ChIL-Alternative to ChIP-Seq ..................................................... 52
3.5.1.2 Epigenetic Time of Flight (EpiTOF) ................................................................... 52
3.5.2 Expanding Epigenetic Applications in Non-Oncology Diseases ............53
4. Competitive Landscape .............................................................54
4.1 Overview...........................................................................................................55
4.2 Synergistic Activities ......................................................................................55
4.3 Product Launches ...........................................................................................56
4.4 Product Approvals...........................................................................................57
4.5 Mergers and Acquisitions...............................................................................58
4.6 Other Business Activities ...............................................................................58
4.7 Market Share Analysis, 2019-2020 .................................................................59
4.8 Growth Share Analysis (Company)................................................................61
4.9 Growth Share Analysis (Technology) ............................................................62
5. Products, $Million, 2020-2031 ....................................................64
5.1 Overview...........................................................................................................65
5.2 Consumables ...................................................................................................66
5.2.1 Kits and Assays...........................................................................................67

5. 5
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
5.2.2 Reagents and Enzymes ..............................................................................69
5.2.3 Other Consumables ....................................................................................70
5.3 Instruments ......................................................................................................71
5.4 Software ...........................................................................................................72
6. Mechanism ................................................................................74
6.1 Overview...........................................................................................................75
6.2 DNA Methylation..............................................................................................76
6.3 Histone Modification .......................................................................................77
6.4 RNA Modification.............................................................................................78
6.5 Other Mechanisms...........................................................................................79
7. Technology................................................................................80
7.1 Overview...........................................................................................................81
7.2 Polymerase Chain Reaction (PCR).................................................................83
7.2.1.1 Real-Time PCR (RT-PCR)................................................................................. 84
7.2.1.2 Digital PCR (dPCR) ........................................................................................... 85
7.2.2 Sequencing ..................................................................................................87
7.2.2.1 Next-Generation Sequencing (NGS) ................................................................. 88
7.2.2.2 Traditional Sequencing (Sanger Sequencing) ................................................... 89
7.3 Microarray ........................................................................................................90
7.4 Other Technologies (MS, Flow Cytometry)....................................................92
8. Application ................................................................................93
8.1 Overview...........................................................................................................94
8.2 Oncology ..........................................................................................................95
8.2.1 Clinical Application in Oncology................................................................96
8.2.2 Translational Research Application in Oncology.....................................97
8.3 Metabolic Diseases..........................................................................................98
8.3.1 Clinical Application in Metabolic Diseases ...............................................99
8.3.2 Translational Research Application in Metabolic Diseases ..................100
8.4 Immunology ...................................................................................................101
8.4.1 Clinical Application in Immunology.........................................................102

6. 6
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
8.4.2 Translational Research Application in Immunology ..............................102
8.5 Cardiovascular Diseases ..............................................................................103
8.5.1 Clinical Application in Cardiovascular Diseases....................................104
8.5.2 Translational Research Application in Cardiovascular Diseases .........106
8.6 Other Applications.........................................................................................107
8.6.1 Clinical Application in Other ....................................................................107
8.6.2 Translational Research Application.........................................................108
9. End User..................................................................................110
9.1 Overview.........................................................................................................111
9.2 Pharmaceutical and Biotechnology Companies.........................................112
9.3 Academic and Research Institutions ...........................................................113
9.4 Contract Research Organizations (CROs)...................................................114
9.5 Other End Users ............................................................................................115
10. Region .....................................................................................116
10.1 Overview.........................................................................................................117
10.2 North America................................................................................................121
10.2.1 U.S. .............................................................................................................123
10.2.2 Canada .......................................................................................................124
10.3 Europe ............................................................................................................127
10.3.1 Germany.....................................................................................................129
10.3.2 France.........................................................................................................130
10.3.3 U.K. .............................................................................................................131
10.3.4 Italy .............................................................................................................132
10.3.5 Spain...........................................................................................................133
10.3.6 Rest-of-Europe...........................................................................................134
10.4 Asia-Pacific ....................................................................................................136
10.4.1 China ..........................................................................................................138
10.4.2 India............................................................................................................139
10.4.3 Japan..........................................................................................................140
10.4.4 South Korea ...............................................................................................141

7. 7
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
10.4.5 Australia.....................................................................................................142
10.4.6 Rest-of-Asia-Pacific (RoAPAC) ................................................................143
10.5 Latin America.................................................................................................144
10.5.1 Brazil...........................................................................................................146
10.5.2 Mexico ........................................................................................................147
10.5.3 Rest-of-Latin America (RoLA) ..................................................................148
10.6 Rest-of-the-World ..........................................................................................149
11. Company Profiles....................................................................150
11.1 Overview.........................................................................................................151
11.2 Thermo Fisher Scientific Inc.........................................................................152
11.2.1 Company Overview ...................................................................................152
11.2.2 Role of Thermo Fisher Scientific Inc. in the Global Epigenetics
Market...................................................................................................152
11.2.3 Financials...................................................................................................153
11.2.4 Key Insights About Financial Health of the Company ...........................155
11.2.5 SWOT Analysis..........................................................................................156
11.3 QIAGEN N.V....................................................................................................157
11.3.1 Company Overview ...................................................................................157
11.3.2 Role of QIAGEN N.V. in the Global Epigenetics Market .........................157
11.3.3 Financials...................................................................................................159
11.3.4 Key Insights About Financial Health of the Company ...........................161
11.3.5 SWOT Analysis..........................................................................................162
11.4 F. Hoffmann-La Roche Ltd............................................................................163
11.4.1 Company Overview ...................................................................................163
11.4.2 Role of F. Hoffmann-La Roche Ltd. in the Global Epigenetics Market
..............................................................................................................163
11.4.3 Financials...................................................................................................165
11.4.4 Key Insights About Financial Health of the Company ...........................166
11.4.5 SWOT Analysis..........................................................................................167
11.5 Bio-Rad Laboratories, Inc. ............................................................................168

8. 8
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
11.5.1 Company Overview ...................................................................................168
11.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Epigenetics Market
..............................................................................................................168
11.5.3 Financials...................................................................................................169
11.5.4 Key Insights About Financial Health of the Company ...........................171
11.5.5 SWOT Analysis..........................................................................................172
11.6 Illumina, Inc....................................................................................................173
11.6.1 Company Overview ...................................................................................173
11.6.2 Role of Illumina, Inc. in the Global Epigenetics Market .........................173
11.6.3 Financials...................................................................................................174
11.6.4 Key Insights About Financial Health of the Company ...........................176
11.6.5 SWOT Analysis..........................................................................................177
11.7 PerkinElmer Inc..............................................................................................178
11.7.1 Company Overview ...................................................................................178
11.7.2 Role of PerkinElmer Inc. in the Global Epigenetics Market ...................178
11.7.3 Financials...................................................................................................179
11.7.4 Key Insights About Financial Health of the Company ...........................182
11.7.5 SWOT Analysis..........................................................................................183
11.8 Exact Sciences Corporation .........................................................................184
11.8.1 Company Overview ...................................................................................184
11.8.2 Role of Exact Sciences Corporation in the Global Epigenetics
Market...................................................................................................184
11.8.3 Financials...................................................................................................186
11.8.4 Key Insights About Financial Health of the Company ...........................188
11.8.5 SWOT Analysis..........................................................................................189
11.9 Merck KGaA ...................................................................................................190
11.9.1 Company Overview ...................................................................................190
11.9.2 Role of Merck KGaA in the Global Epigenetics Market..........................190
11.9.3 Financials...................................................................................................191
11.9.4 Key Insights About Financial Health of the Company ...........................193

9. 9
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
11.9.5 SWOT Analysis..........................................................................................194
11.10 MDxHealth ......................................................................................................195
11.10.1 Company Overview ...................................................................................195
11.10.2 Role of MDxHealth in the Global Epigenetics Market.............................195
11.10.3 Financials...................................................................................................197
11.10.4 Key Insights About Financial Health of the Company ...........................199
11.10.5 SWOT Analysis..........................................................................................200
11.11 Agilent Technologies, Inc. ............................................................................201
11.11.1 Company Overview ...................................................................................201
11.11.2 Role of Agilent Technologies, Inc. in the Global Epigenetics Market
..............................................................................................................201
11.11.3 Financials...................................................................................................202
11.11.4 Key Insights About Financial Health of the Company ...........................205
11.11.5 SWOT Analysis..........................................................................................206
11.12 Abcam Plc ......................................................................................................207
11.12.1 Company Overview ...................................................................................207
11.12.2 Role of Abcam Plc in the Global Epigenetics Market.............................207
11.12.3 Financials...................................................................................................208
11.12.4 SWOT Analysis..........................................................................................210
11.13 Pacific Biosciences of California, Inc. .........................................................211
11.13.1 Company Overview ...................................................................................211
11.13.2 Role of Pacific Biosciences of California, Inc. in the Global
Epigenetics Market..............................................................................211
11.13.3 Financials...................................................................................................213
11.13.4 Key Insights About Financial Health of the Company ...........................215
11.13.5 SWOT Analysis..........................................................................................216
11.14 Zymo Research Corporation.........................................................................217
11.14.1 Company Overview ...................................................................................217
11.14.2 Role of Zymo Research Corporation in the Global Epigenetics
Market...................................................................................................217

10. 10
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
11.14.3 SWOT Analysis..........................................................................................219
11.15 Active Motif, Inc. ............................................................................................220
11.15.1 Company Overview ...................................................................................220
11.15.2 Role of Active Motif, Inc. in the Global Epigenetics Market...................220
11.15.3 SWOT Analysis..........................................................................................222
11.16 Promega Corporation....................................................................................223
11.16.1 Company Overview ...................................................................................223
11.16.2 Role of Promega Corporation in the Global Epigenetics Market ..........223
11.16.3 SWOT Analysis..........................................................................................224

11. 11
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
List of Figures
Figure 1: Global Cancer Burden-2020
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Epigenetics
Market
Figure 3: Global Epigenetics Market (by Product), $Million, 2020 and 2031
Figure 4: Global Epigenetics Market (by Mechanism), $Million, 2020 and 2031
Figure 5: Global Epigenetics Market (by Technology), $Million, 2020 and 2031
Figure 6: Global Epigenetics Market (by Application), $Million, 2020 and 2031
Figure 7: Global Epigenetics Market Snapshot
Figure 8: Global Epigenetics Market: Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Top-Down Approach (Segment-Wise Analysis)
Figure 12: Global Epigenetics Market Segmentation
Figure 13: Global Epigenetics Market, $Million, 2020-2031
Figure 14: Global Epigenetics Market: COVID-19 Impact Analysis
Figure 15: Global Cancer Burden-2020
Figure 16: Share of Key Developments and Strategies, January 2017-October 2021
Figure 17: Share of Synergistic Activities (by Company), January 2017-October 2021
Figure 18: Number of Product Launches (by Company), January 2017-October 2021
Figure 19: Share of Product Approvals (by Company), January 2017- October 2021
Figure 20: Share of Mergers and Acquisitions (by Company), January 2017– October 2021
Figure 21: Share of Other Business Activities (by Company), January 2017-October 2021
Figure 22: Market Share Analysis for Global Epigenetics Market, $Million, 2019 and 2020
Figure 23: Growth Share Analysis for Global Epigenetics Market (by Company), 2020
Figure 24: Growth Share Analysis for Global Epigenetics Market (by Technology), 2020-2031
Figure 25: Global Epigenetics Market (by Product)
Figure 26: Global Epigenetics Market (by Product), $Million, 2020 and 2031
Figure 27: Global Epigenetics Market (Consumables), $Million, 2020-2031
Figure 28: Global Epigenetics Market (Kits and Assays), $Million, 2020-2031
Figure 29: Global Epigenetics Market (Reagents and Enzymes), $Million, 2020-2031
Figure 30: Global Epigenetics Market (Other Consumables), $Million, 2020-2031
Figure 31: Global Epigenetics Market (Instruments), $Million, 2020-2031
Figure 32: Global Epigenetics Market (Software), $Million, 2020-2031
Figure 33: Global Epigenetics Market (Mechanism)
Figure 34: Global Epigenetics Market (Mechanism), $Million, 2020 and 2031
Figure 35: Global Epigenetics Market (DNA Methylation), $Million, 2020-2031
Figure 36: Global Epigenetics Market (Histone Modification), $Million, 2020-2031

12. 12
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
Figure 37: Global Epigenetics Market (RNA Modification), $Million, 2020-2031
Figure 38: Global Epigenetics Market (Other Mechanisms), $Million, 2020-2031
Figure 39: Global Epigenetics Market (by Technology)
Figure 40: Global Epigenetics Market (by Technology), $Million, 2020 and 2031
Figure 41: Global Epigenetics Market (Polymerase Chain Reaction (PCR)), $Million, 2020-2031
Figure 42: Global Epigenetics Market (RT-PCR), $Million, 2020-2031
Figure 43: Global Epigenetics Market (dPCR), $Million, 2020-2031
Figure 44: Global Epigenetics Market (Sequencing), $Million, 2020-2031
Figure 45: Global Epigenetics Market (by Sequencing), $Million, 2020 and 2031
Figure 46: Global Epigenetics Market (NGS), $Million, 2020-2031
Figure 47: Global Epigenetics Market (Sanger Sequencing), $Million, 2020-2031
Figure 48: Global Epigenetics Market (Microarray), $Million, 2020-2031
Figure 49: Global Epigenetics Market (Other Technologies), $Million, 2020-2031
Figure 50: Global Epigenetics Market (by Application)
Figure 51: Global Epigenetics Market (by Application), $Million, 2020 and 2031
Figure 52: Global Epigenetics Market (Oncology), $Million, 2020-2031
Figure 53: Global Epigenetics Market (Clinical Application in Oncology), $Million, 2020-2031
Figure 54: Global Epigenetics Market (Translational Research Application in Oncology), $Million,
2020-2031
Figure 55: Global Epigenetics Market (Metabolic Diseases), $Million, 2020-2031
Figure 56: Global Epigenetics Market (Clinical Application in Metabolic Diseases), $Million, 2020-
2031
Figure 57: Global Epigenetics Market (Translational Research Application in Metabolic Diseases),
$Million, 2020-2031
Figure 58: Global Epigenetics Market (Immunology), $Million, 2020-2031
Figure 59: Global Epigenetics Market (Clinical Application in Immunology), $Million, 2020-2031
Figure 60: Global Epigenetics Market (Translational Research Application in Immunology), $Million,
2020-2031
Figure 61: Global Epigenetics Market (Cardiovascular Diseases), $Million, 2020-2031
Figure 62: Global Epigenetics Market (Clinical Application in Cardiovascular Diseases), $Million,
2020-2031
Figure 63: Global Epigenetics Market (Translational Research Application in Cardiovascular
Diseases), $Million, 2020-2031
Figure 64: Global Epigenetics Market (Other Applications), $Million, 2020-2031
Figure 65: Global Epigenetics Market (Clinical Application in Other), $Million, 2020-2031
Figure 66: Global Epigenetics Market (Translational Research Application), $Million, 2020-2031
Figure 67: Global Epigenetics Market (by End User)
Figure 68: Global Epigenetics Market (by End User), $Million, 2020 and 2031
Figure 69: Global Epigenetics Market (Pharmaceutical and Biotechnology Companies), $Million,
2020-2031
Figure 70: Global Epigenetics Market (Academic and Research Institutions), $Million, 2020-2031
Figure 71: Global Epigenetics Market (Contract Research Organizations), $Million, 2020-2031

13. 13
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
Figure 72: Global Epigenetics Market (Other End Users), $Million, 2020-2031
Figure 73: Global Epigenetics Market Snapshot (by Region), $Million, 2020-2031
Figure 74: Global Epigenetics Market (by Region), $Million, 2020-2031
Figure 75: Global Epigenetics Market (by Region), $Million, 2020 and 2031
Figure 76: North America Epigenetics Market, $Million, 2020-2031
Figure 77: North America: Market Dynamics
Figure 78: North America Epigenetics Market (by Country), $Million, 2020-2031
Figure 79: U.S. Epigenetics Market, $Million, 2020-2031
Figure 80: Canada Epigenetics Market, $Million, 2020-2031
Figure 81: Europe Epigenetics Market, $Million, 2020-2031
Figure 82: Europe: Market Dynamics
Figure 83: Europe Epigenetics Market (by Country), $Million, 2020-2031
Figure 84: Germany Epigenetics Market, $Million, 2020-2031
Figure 85: France Epigenetics Market, $Million, 2020-2031
Figure 86: U.K. Epigenetics Market, $Million, 2020-2031
Figure 87: Italy Epigenetics Market, $Million, 2020-2031
Figure 88: Spain Epigenetics Market, $Million, 2020-2031
Figure 89: Rest-of-Europe Epigenetics Market, $Million, 2020-2031
Figure 90: Asia-Pacific Epigenetics Market, $Million, 2020-2031
Figure 91: APAC: Market Dynamics
Figure 92: APAC Epigenetics Market (by Country), $Million, 2020-2031
Figure 93: China Epigenetics Market, $Million, 2020-2031
Figure 94: India Epigenetics Market, $Million, 2020-2031
Figure 95: Japan Epigenetics Market, $Million, 2020-2031
Figure 96: South Korea Epigenetics Market, $Million, 2020-2031
Figure 97: Australia Epigenetics Market, $Million, 2020-2031
Figure 98: RoAPAC Epigenetics Market, $Million, 2020-2031
Figure 99: Latin America Epigenetics Market, $Million, 2020-2031
Figure 100: Latin America: Market Dynamics
Figure 101: Global Epigenetics Market (by Country), $Million, 2020-2031
Figure 102: Brazil Epigenetics Market, $Million, 2020-2031
Figure 103: Mexico Epigenetics Market, $Million, 2020-2031
Figure 104: Rest-of-Latin America (RoLA) Epigenetics Market, $Million, 2020-2031
Figure 105: Rest-of-the-World (RoW) Epigenetics Market, $Million, 2020-2031
Figure 106: Total Number of Companies Profiled
Figure 107: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 108: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2018-2020
Figure 109: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 110: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018-2020

14. 14
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
Figure 111: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
Figure 112: Thermo Fisher Scientific Inc: SWOT Analysis
Figure 113: QIAGEN N.V.: Product Portfolio
Figure 114: QIAGEN N.V.: Overall Financials, $Million, 2018-2020
Figure 115: QIAGEN N.V.: Revenue (by Segment), $Million, 2018-2020
Figure 116: QIAGEN N.V.: Revenue (by Region), $Million, 2018-2020
Figure 117: QIAGEN N.V.: R&D Expenditure, $Million, 2018-2020
Figure 118: QIAGEN N.V.: SWOT Analysis
Figure 119: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 120: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2018-2020
Figure 121: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2018-2020
Figure 122: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2018-2020
Figure 123: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2018-2020
Figure 124: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 125: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 126: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2018-2020
Figure 127: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 128: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 129: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 130: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 131: Illumina Inc, Product Portfolio
Figure 132: Illumina, Inc: Overall Financials, $Million, 2018-2020
Figure 133: Illumina, Inc. Revenue (by Segment), $Million, 2018-2020
Figure 134: Illumina, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 135: Illumina, Inc: R&D Expenditure, $Million, 2018-2020
Figure 136: Illumina, Inc: SWOT Analysis
Figure 137: PerkinElmer Inc.: Product Portfolio
Figure 138: PerkinElmer Inc.: Overall Financials, $Million, 2018-2020
Figure 139: PerkinElmer Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 140: PerkinElmer Inc.: Revenue (by Region), $Million, 2018-2020
Figure 141: PerkinElmer Inc.: R&D Expenditure, $Million, 2018-2020
Figure 142: PerkinElmer Inc.: SWOT Analysis
Figure 143: Exact Sciences Corporation: Service Portfolio
Figure 144: Exact Sciences Corporation: Overall Financials, $Million, 2018-2020
Figure 145: Exact Sciences Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 146: Exact Sciences Corporation: Revenue (by Region), $Million, 2018-2020
Figure 147: Exact Sciences Corporation: R&D Expenditure, $Million, 2018-2020
Figure 148: Figure 14.19: Exact Sciences Corporation: SWOT Analysis
Figure 149: Merck KGaA: Product Portfolio

15. 15
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
Figure 150: Merck KGaA: Overall Financials, $Million, 2018-2020
Figure 151: Merck KGaA: Revenue (by Segment), $Million, 2018-2020
Figure 152: Merck KGaA: Revenue (by Region), $Million, 2018-2020
Figure 153: Merck KGaA: R&D Expenditure, $Million, 2018-2020
Figure 154: Merck KGaA: SWOT Analysis
Figure 155: MDxHealth: Service Portfolio
Figure 156: MDxHealth: Overall Financials, $Million, 2018-2020
Figure 157: MDxHealth: Revenue (by Segment), $Million, 2018-2020
Figure 158: MDxHealth: Revenue (by Region), $Million, 2018-2020
Figure 159: MDxHealth: R&D Expenditure, $Million, 2018-2020
Figure 160: MDxHealth: SWOT Analysis
Figure 161: Agilent Technologies, Inc.: Product Portfolio
Figure 162: Agilent Technologies, Inc.: Overall Financials, $Million, 2018-2020
Figure 163: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 164: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 165: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 166: Agilent Technologies, Inc.: SWOT Analysis
Figure 167: Abcam Plc: Service Portfolio
Figure 168: Abcam Plc: Overall Financials, $Million, 2018-2020
Figure 169: Abcam Plc: Revenue (by Region), $Million, 2018-2020
Figure 170: Abcam Plc: SWOT Analysis
Figure 171: Pacific Biosciences of California, Inc. Product Portfolio
Figure 172: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2018-2020
Figure 173: Pacific Biosciences of California, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 174: Pacific Biosciences of California, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 175: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 176: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 177: Zymo Research Corporation: Product Portfolio
Figure 178: Zymo Research Corporation: SWOT Analysis
Figure 179: Active Motif, Inc.: Product Portfolio
Figure 180: Active Motif, Inc.: SWOT Analysis
Figure 181: Promega Corporation.: Product Portfolio
Figure 182: Promega Corporation Inc., SWOT Analysis

16. 16
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
List of Tables
Table 1: Key Coverage Providers for Epigenetics Tests
Table 2: Likert Scale
Table 3: Impact Analysis of Market Drivers
Table 4: Impact Analysis of Market Restraints
Table 5: Products and Prices
Table 6: Companies Providing Kits and Assays
Table 7: Companies Offering Reagents and Enzymes
Table 8: Companies Offering Other Consumables
Table 9: Companies Offering Instruments
Table 10: Companies Offering Software
Table 11: RT-PCR-Based Epigenetics Products
Table 12: dPCR-Based Epigenetics Products
Table 13: NGS-Based Epigenetics Products

17. 17
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

18. 18
All rights reserved at BIS Research Inc.
E
p
i
g
e
n
e
t
i
c
s
M
a
r
k
e
t
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com